Hypogonadism in male cancer patients
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Prevalence of hypogonadism in men with cancer has been reported between 40% and 90%, which is significantly higher than in the general population. Hypogonadism is likely to affect the quality of life in these patients by contributing to non‐specific symptoms, including decreased energy, anorexia, sarcopenia, weight loss, depression, insomnia, fatigue, weakness, and sexual dysfunction. Pathogenesis of hypogonadism in cancer patients is thought to be multi‐factorial. Inflammation may play an important role, but leptin, opioids, ghrelin, and high‐dose chemotherapy through different mechanisms have all been implicated as the cause. Hypogonadism is also associated with poor survival in cancer patients. Data looking into the treatment of hypogonadal male cancer patients with testosterone are limited. However, improvements in body weight, muscle strength, lean body mass, and quality of life have been shown in hypogonadal men with other chronic diseases on testosterone replacement therapy. Prospective and interventional trials are needed to test the efficacy and safety of testosterone treatment in improving quality of life of these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760
Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency
Farooqi, I. S., Jebb, S. A., Langmack, G., Lawrence, E., Cheetham, C. H., Prentice, A. M., Hughes, I. A., McCamish, M. A., & O'Rahilly, S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411204 · Cited by 1,998 · cited 1×
“Both animal and human models have shown that restoring normal levels of leptin results in normalization of the hypothalamic–pituitary–gonadal axis and reversal of infertility and delayed puberty [22, 23], providing further support to this hypothesis.”
BackgroundRecombinant human leptin in women with hypothalamic amenorrhea
Welt, C. K., Chan, J. L., Bullen, J., Murphy, R., Smith, P., DePaoli, A. M., Karalis, A., & Mantzoros, C. S. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040388 · Cited by 908
Prevalence of hypogonadism in males aged at least 45 years: the HIM study
MULLIGAN, T., FRICK, M. F., ZURAW, Q. C., STEMHAGEN, A., & MCWHIRTER, C. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.00992.x · Cited by 767 · cited 1×
“In the Hypogonadism in Male (HIM) study which included 2,162 men older than 45 years of age in the primary care setting, the crude prevalence of hypogonadism (defined as total testosterone <300 ng/dl) was 39% [6].”
BackgroundMalkin, C. J., Pugh, P. J., Jones, R. D., Kapoor, D., Channer, K. S., & Jones, T. H. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031069 · Cited by 731
Validation of a screening questionnaire for androgen deficiency in aging males
Morley, J. E., Charlton, E., Patrick, P., Kaiser, F. E., Cadeau, P., McCready, D., & Perry, H. M. (2000) · Metabolism · doi:10.1053/meta.2000.8625 · Cited by 662 · cited 1×
“In non-cancer, hypogonadal men, testosterone replacement has a positive effect on several parameters that are also impaired in the setting of cancer, and treatment of hypogonadism is clinically indicated in symptomatic men with low testosterone [53].”
BackgroundWang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A. M., Snyder, P. J., Weber, T., Berman, N., Hull, L., & Swerdloff, R. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032006 · Cited by 656 · cited 1×
“Sexual function and mood parameters improve rapidly and are maintained throughout testosterone treatment [56, 57].”
BackgroundAraujo, A. B., O’Donnell, A. B., Brambilla, D. J., Simpson, W. B., Longcope, C., Matsumoto, A. M., & McKinlay, J. B. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031719 · Cited by 591
Endocrine consequences of long-term intrathecal administration of opioids
Abs, R., Verhelst, J., Maeyaert, J., Van Buyten, J.-P., Opsomer, F., Adriaensen, H., Verlooy, J., Van Havenbergh, T., Smet, M., & Van Acker, K. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6615 · Cited by 491
Hypogonadism in men consuming sustained-action oral opioids
Daniell, H. W. (2002) · The Journal of Pain · doi:10.1054/jpai.2002.126790 · Cited by 401
Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids
Rajagopal, A., Vassilopoulou‐Sellin, R., Palmer, J. L., Kaur, G., & Bruera, E. (2004) · Cancer · doi:10.1002/cncr.20028 · Cited by 206 · cited 2×
“In another study, 18 out of 20 of male cancer survivors who had received high-dose opioids orally had lower total testosterone level compared to 8 out of 20 matched cancer survivors who did not receive opioids [8].”
BackgroundSvartberg, J., Agledahl, I., Figenschau, Y., Sildnes, T., Waterloo, K., & Jorde, R. (2008) · International Journal of Impotence Research · doi:10.1038/ijir.2008.19 · Cited by 160 · cited 1×
“Furthermore, testosterone administration has been shown to increase lean body mass and bone mineral density, to improve quality of life, and to decrease fatigue in this setting [54, 55].”
BackgroundHypogonadism in patients treated with intrathecal morphine
Finch, P. M., Roberts, L. J., Price, L., Hadlow, N. C., & Pullan, P. T. (2000) · The Clinical Journal of Pain · doi:10.1097/00002508-200009000-00011 · Cited by 144 · cited 1×
“of causing secondary hypogonadism in non-cancer patients with pain [33–35].”
BackgroundLanfranco, F., Bonelli, L., Baldi, M., Me, E., Broglio, F., & Ghigo, E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0049 · Cited by 112
Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women
Fraser, L.-A., Morrison, D., Morley-Forster, P., Paul, T., Tokmakejian, S., Larry Nicholson, R., Bureau, Y., Friedman, T., & Uum, S. H. M. V. (2008) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2008-1076715 · Cited by 112 · cited 1×
“reported a hypogonadism prevalence of 75% inmale cancer subjects receiving oral opioids for chronic pain [40].”
BackgroundStrasser, F., Palmer, J. L., Schover, L. R., Yusuf, S. W., Pisters, K., Vassilopoulou‐Sellin, R., DeGracia, B., Willey, J. S., & Bruera, E. (2006) · Cancer · doi:10.1002/cncr.22339 · Cited by 112
Dose-Dependent Effects of Recombinant Human Interleukin-6 on the Pituitary-Testicular Axis
Tsigos, C., Papanicolaou, D. A., Kyrou, I., Raptis, S. A., & Chrousos, G. P. (1999) · Journal of Interferon & Cytokine Research · doi:10.1089/107999099312948 · Cited by 111
Andropause: is androgen replacement therapy indicated for the aging male?
Hijazi, R. A., & Cunningham, G. R. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104518 · Cited by 105
Cited by
Cachexia: A systemic consequence of progressive, unresolved disease
Ferrer, M., Anthony, T. G., Ayres, J. S., Biffi, G., Brown, J. C., Caan, B. J., Cespedes Feliciano, E. M., Coll, A. P., Dunne, R. F., Goncalves, M. D., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.028 · Cited by 260
Treatment of cachexia: an overview of recent developments
von Haehling, S., & Anker, S. D. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2014.09.007 · Cited by 79
Veldhuis, J., Yang, R., Roelfsema, F., & Takahashi, P. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3611 · Cited by 65
Rossetti, M. L., Esser, K. A., Lee, C., Tomko, R. J., Eroshkin, A. M., & Gordon, B. S. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00177.2019 · Cited by 37
Metadata
- Authors
- Burney, B. O., & Garcia, J. M.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2012-04-20
- Volume
- 3
- Issue
- 3
- Pages
- 149-155
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- OpenAlex
- W2051150857
- Cited by
- 53
- References
- 18
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.